Feldman W
Department of Pediatrics, University of Ottawa, Ontario, Canada.
J Gen Intern Med. 1990 Sep-Oct;5(5 Suppl):S50-3. doi: 10.1007/BF02600842.
The adverse effects of screening are not commonly studied. False-positive tests lead to discomfort, costs, and risks from additional diagnostic and therapeutic procedures. False-negative tests lead to a sense of security and delays in seeking medical help when symptoms develop. Labeling an individual with a false-positive test, or with a true-positive test for which there is no evidence that intervention makes a difference, e.g., intervention on an 80-year-old asymptomatic woman with hypercholesterolemia, can have a markedly negative impact on the quality of life. Interpreting statistical abnormalities out of clinical context, e.g., lending importance to a multiphasic blood screen showing "high" alkaline phosphatase in a teenager, leads to unnecessary costs and anxiety. The cost of screening programs that may not have been shown to do more good than harm is already having an impact on the resources available to diagnose and treatment symptomatic persons. Premature implementation of unproved screening programs will continue to decrease physician and public confidence in prevention.
筛查的不良影响通常未得到充分研究。假阳性检测会导致不适、成本增加以及额外诊断和治疗程序带来的风险。假阴性检测会使人产生安全感,并且当症状出现时会延迟寻求医疗帮助。给个体贴上假阳性检测的标签,或者给虽为真阳性检测但并无证据表明干预会有效果(例如,对一名80岁无症状高胆固醇血症女性进行干预)的个体贴上标签,可能会对生活质量产生显著负面影响。脱离临床背景解读统计异常情况,例如,过分看重青少年多相血液筛查中显示“高”碱性磷酸酶的结果,会导致不必要的成本和焦虑。那些可能未被证明利大于弊的筛查项目的成本,已经在影响用于诊断和治疗有症状患者的可用资源。过早实施未经证实的筛查项目将继续降低医生和公众对预防的信心。